Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LSS | P48449 | 3/20 | 0.38 |
| ▸ | FABP4 | P15090 | 3/20 | 0.36 |
| ▸ | IDO1 | P14902 | 2/20 | 0.36 |
| ▸ | FABP3 | P05413 | 2/20 | 0.36 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.35 |
| ▸ | ALOX5AP | P20292 | 4/20 | 0.35 |
| ▸ | FEN1 | P39748 | 4/20 | 0.35 |
| ▸ | SCN9A | Q15858 | 3/20 | 0.35 |
| ▸ | PDE10A | Q9Y233 | 2/20 | 0.34 |
| ▸ | SCN5A | Q14524 | 1/20 | 0.34 |
| ▸ | SOS1 | Q07889 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21113919 | 0.94 | LSS (0.42) | LSSFABP4IDO1FABP3PDK2 | |
| SCHEMBL21113927 | 0.92 | PDK2 (0.38) | LSSPDK2KDM4EALOX5APFEN1 | |
| SCHEMBL21114007 | 0.88 | PDK2 (0.34) | LSSPDK2KDM4EALOX5APFEN1 | |
| SCHEMBL21114023 | 0.86 | LSS (0.43) | LSSIDO1PDK2 | |
| SCHEMBL21114177 | 0.82 | LSS (0.37) | LSSPDK2KDM4EALOX5APFEN1 | |
| SCHEMBL21114181 | 0.80 | ALOX5AP (0.39) | LSSFABP4FABP3KDM4EALOX5AP | |
| SCHEMBL21114184 | 0.80 | KDM4E (0.46) | FABP4FABP3PDK2KDM4EALOX5AP | |
| SCHEMBL21122126 | 0.79 | PDK2 (0.46) | LSSPDK2 | |
| SCHEMBL21122128 | 0.78 | LSS (0.36) | LSSKDM4EALOX5APFEN1 | |
| SCHEMBL21113920 | 0.76 | LSS (0.39) | LSSFABP4IDO1FABP3ALOX5AP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2019136314-A1 | COMPOUNDS AND METHODS FOR TREATMENT OF CYSTIC FIBROSIS | THE CURATORS OF THE UNIVERSITY OF MISSOURI (US) | 2019-07-11 | — | — | WO | disclosed |
| US-20190210973-A1 | COMPOUNDS AND METHODS FOR TREATMENT OF CYSTIC FIBROSIS | NATIONAL INSTITUTES OF HEALTH - DIRECTOR DEITR | 2019-07-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190210973-A1 | COMPOUNDS AND METHODS FOR TREATMENT OF CYSTIC FIBROSIS | CFTR, SLC26A4, SERPINB1 | LSS 438/4885FABP4 3192/4885IDO1 4287/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.